EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib

Jonathan W Riess iD, Adrianus J de Langen iD, Santiago Ponce, Sarah B Goldberg iD, Zofia Piotrowska iD, Jonathan W Goldman iD, Xiuning Le iD, Byoung Chul Cho iD, Yasuto Yoneshima, Helen Ambrose, Riccardo Cavazzina, Kwan Ho Tang iD und 2 weitere

JCO Precision Oncology · 2025-06 · (9)

DOI: 10.1200/po-24-00818 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift JCO Precision Oncology, 2025-06. Verfasst von Jonathan W Riess und 13 weiteren Autor:innen. Beteiligte Einrichtung: UC Davis Comprehensive Cancer Center, Sacramento, CA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Aniline Compounds, Acrylamides, Lung Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE ORCHARD (ClinicalTrials.gov identifier: NCT03944772 ) is a phase II, biomarker-directed platform study designed to characterize resistance mechanisms and evaluate novel drug combinations in patients with epidermal growth factor receptor ( EGFR )–mutated advanced non–small cell lung cancer who have progressed on first-line osimertinib. We report final results of the module assessing the efficacy and safety of osimertinib plus necitumumab (a monoclonal antibody that blocks EGFR) in patients with ≥one of the following: EGFR amplification or select secondary EGFR alterations (L718 or G724 mutation, or exon 20 insertion). MATERIALS AND METHODS Patients received osimertinib (80 mg orally once daily) plus necitumumab (800 mg intravenously, days 1 and 8 of a 3-week cycle) until disease progression or unacceptable toxicity. The primary end point was objective response rate (ORR) per RECIST 1.1 by investigator assessment. RESULTS Overall, 19 patients received osimertinib plus necitumumab; at data cutoff (April 18, 2023), all patients had discontinued treatment. The ORR was 11% (80% CI, 3 to 26); two patients had a confirmed partial response, with duration of response of 10.4 and 6.0 months; both patients had EGFR amplification. The median progression-free survival was 4.0 months (95% CI, 1.3 to 5.4) and the overall survival was 11.4 months (95% CI, 6.6 to 15.5). Ten patients (53%) had grade ≥3 adverse events, most commonly embolism (not otherwise specified, pulmonary embolism or deep vein thrombosis, reported in four patients; 21%). The safety profile of the combination was consistent with the known profiles of the two individual drugs, and no new signals were identified. CONCLUSION Osimertinib plus necitumumab demonstrated modest clinical benefit, and the overall risk-benefit analysis indicates that further evaluation of the regimen is not warranted in these molecularly defined subsets of osimertinib resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAniline CompoundsAcrylamidesLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, HumanizedHumansMaleErbB ReceptorsFemaleMiddle AgedAgedMutationAdultAged, 80 and overDisease ProgressionIndolesPyrimidines

Substanzen

osimertinibAniline CompoundsAcrylamidesErbB ReceptorsnecitumumabEGFR protein, humanAntibodies, Monoclonal, HumanizedIndolesPyrimidines

Autor:innen und Institutionen

  • UC Davis Comprehensive Cancer Center, Sacramento, CA.
  • Department of Thoracic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • Department of Medical Oncology, Hospital Universitario and Centro Nacional de Investigaciones Oncologicas, Madrid, Spain.
  • Department of Medicine (Medical Oncology), Yale School of Medicine, New Haven, CT.
  • Department of Medicine, Massachusetts General Hospital, Boston, MA.
  • David Geffen School of Medicine at UCLA, Los Angeles, CA.

ORCID-Profile: Jonathan W Riess, Adrianus J de Langen, Sarah B Goldberg, Zofia Piotrowska, Jonathan W Goldman, Xiuning Le, Byoung Chul Cho, Kwan Ho Tang, Helena A Yu

Zitieren

APA

Riess, J. W., de Langen, A. J., Ponce, S., Goldberg, S. B., Piotrowska, Z., Goldman, J. W., Le, X., Cho, B. C., Yoneshima, Y., Ambrose, H., Cavazzina, R., Tang, K. H., Lau, J., & Yu, H. A. (2025). ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib. JCO Precision Oncology. https://doi.org/10.1200/po-24-00818

Vancouver

Riess JW, de Langen AJ, Ponce S, Goldberg SB, Piotrowska Z, Goldman JW, et al. ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib. JCO Precision Oncology. 2025. doi:10.1200/po-24-00818

BibTeX
@article{Riess2025,
  author = {Riess, Jonathan W and de Langen, Adrianus J and Ponce, Santiago and Goldberg, Sarah B and Piotrowska, Zofia and Goldman, Jonathan W and Le, Xiuning and Cho, Byoung Chul and Yoneshima, Yasuto and Ambrose, Helen and Cavazzina, Riccardo and Tang, Kwan Ho and Lau, James and Yu, Helena A},
  title = {ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib},
  journal = {JCO Precision Oncology},
  year = {2025},
  number = {9},
  doi = {10.1200/po-24-00818}
}
Kostenlos starten →